ArticleFrontiers in immunology2025
Primary antiphospholipid syndrome presenting with unilateral renal infarction and C4d-positive cortical necrosis: a case report with a pooled analysis of 24 cases.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary antiphospholipid syndrome (APS) is an autoimmune thrombophilic disorder characterized by recurrent venous or arterial thrombosis and/or pregnancy morbidity in the presence of persistent antiphospholipid antibodies (aPL). Renal involvement in APS is heterogeneous and may include renal artery thrombosis, renal vein thrombosis, thrombotic microangiopathy, and chronic APS nephropathy. However, unilateral renal infarction as the first and isolated manifestation of primary APS is exceedingly rare. We report a 23-year-old man with no prior medical history who presented with fever, flank pain, and hematuria and was found to have unilateral left renal infarction with cortical necrosis. Imaging showed a slender mid-to-distal segmental defect in the left renal artery with markedly reduced perfusion and extensive cortical non-enhancement. Laboratory testing revealed persistent lupus anticoagulant (LA) and high-titer anticardiolipin antibody (aCL) IgG, fulfilling criteria for primary APS. A percutaneous renal biopsy, performed to clarify the mechanism of injury and exclude immune-complex glomerulonephritis or primary vasculitis, demonstrated diffuse cortical necrosis with fibrin-rich thrombi in small arteries and intense C4d deposition along glomerular capillary and small arterial walls, without immune-complex deposition. We also conducted a pooled analysis of 24 APS cases with renal infarction identified in the literature. Most involved arterial thrombosis, often in young patients, with variable outcomes depending on laterality and timeliness of anticoagulation. Our case underscores several key teaching points (1): APS should be considered in young patients with unexplained renal infarction (2); transient positivity of multiple autoantibodies (including dsDNA, ANCA, and anti-GBM) may be misleading and requires cautious interpretation with repeat testing (3); C4d deposition supports complement-mediated thrombosis as a pathophysiologic mechanism in APS nephropathy; and (4) early diagnosis and anticoagulation are crucial for a favorable outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.